Sign in

CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company

Greenwich LifeSciences, Inc.

Sign in to watch
Ticker
GLSI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
205473709
Phone
203-434-3290
Business address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
  1. 4 Open-market buy CEO and CFO bought 2,400 shares at $11.36 ($27,264)
  2. 4 Open-market buy CEO and CFO bought 3,200 shares at $11.12 ($35,584)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $12.91 ($12,910)
  10. 4 Open-market buy CEO and CFO bought 1,500 shares at $14.63 ($21,945)
  11. 4 Open-market buy VP Clinical Reg Affairs bought 800 shares at $13.85 ($11,080)
  12. 4 Open-market buy CEO and CFO bought 2,000 shares at $13.81 ($27,620)
  13. 4 Open-market buy CEO and CFO bought 5,500 shares at $13.18 ($72,490)
  14. 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $15.15 ($15,150)
  15. 4 Open-market buy CEO and CFO bought 1,500 shares at $15.89 ($23,835)
  16. 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $16.00 ($16,000)
  17. 4 Open-market buy CEO and CFO bought 174,825 shares at $14.30 ($2,499,998)
  18. 4 Open-market buy CEO and CFO bought 3,000 shares at $19.08 ($57,240)
  19. 4 Open-market buy CEO and CFO bought 2,500 shares at $19.98 ($49,950)
  20. 4 Open-market buy CEO and CFO bought 1,500 shares at $17.68 ($26,520)

Page 2 of 8 · 146 filings